lymphoma

[BeiGene, Ltd.] BeiGene, Ltd. announced that BRUKINSA® (zanubrutinib) has received accelerated approval from the US FDA for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen.

[Blood Cancer Journal] In lymphoma patients mean antibody levels and seroconversion rates were lower than in other hematologic malignancies patients, primarily because all nine patients who had received rituximab within six months before COVID-19 failed to produce anti-nucleocapsid and anti-spike-antibody.

[Memorial Sloan Kettering Cancer Center] Memorial Sloan Kettering Cancer Center has received a major grant from the US National Institutes of Health to conduct research related to leukemia.

[Blood Advances] Avelumab was tolerable and demonstrated antitumor activity in heavily pretreated patients with classical Hodgkin lymphoma (cHL), suggesting that PD-L1 blockade may be sufficient for therapeutic benefit in cHL.

[Blood Advances] Researchers showed that tolinapant acted as an efficacious immunomodulatory molecule capable of inducing complete tumor regression in a syngeneic model of T cell lymphoma exclusively in the presence of an intact immune system.

[Communications Biology] The authors synthesize studies characterizing myeloid cell leukemia-1 (MCL1)'s influence on cell proliferation, DNA damage response, autophagy, calcium handling, and mitochondrial quality control to highlight the broader scope that MCL1 plays in cellular homeostasis regulation.